Skip to NavigationSkip to content

New manufacturing boss for MSD

Published on: 10/03/16

MSD has appointed Sanat Chattopadhyay president of the Merck Manufacturing Division (MMD) and an executive vice president of the company. From April 1, he will succeed will succeed Willie Deese, who is to retire on June 1, 2016, after 12 years with the company.

Chattopadhyay is credited with leading MSD out of a troubled period when the company experienced manufacturing issues in its vaccines division, including years of supply limitations with its Shingles vaccine, and MSD describes him as “instrumental” in transforming and growing this part of the business.

Specifically, the company praises his influence on the launch of its blockbuster immunotherapy Keytruda, saying he played a key role in overcoming commercialisation and supply constraints to ensure the launch was delivered in “record time”.

“With more than 30 years of biopharmaceutical industry experience, Sanat has a proven track record of commercialisation, manufacturing and supply chain excellence in therapeutic proteins, vaccines and pharmaceuticals. Under his leadership I am confident that MMD will continue to advance toward its goal of becoming a world-class supplier,” says Kenneth Frazier, chairman and chief executive of MSD.

Chattopadhyay joined the company in 2009 and currently serves as senior vice president of Global Manufacturing Operations (Human Health). 

Joel Levy

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches